ROCHE HOLDING LTD. : Roche reports positive studies of MabThera given by ... 4-traders Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from two studies which showed that a fixed dose of MabThera (rituximab) can be administered subcutaneously (SC), potentially allowing patients to spend less time in infusion centers ... |
